Get started
Author

Tharani Sivakumaran

Observed names: Sivakumaran, Tharani, T. Sivakumaran, Tharani Sivakumaran (13746727)
ORCID: 0000-0001-9738-1580
Observed ORCID: 0000-0001-9738-1580
OpenAlex ID: A5012417874
A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary
2022 · Atara Posner, Owen WJ Prall, et al. · The Journal of Pathology · 27
PDF
Whole genome sequencing improves tissue-of-origin diagnosis and treatment options for cancer of unknown primary
2025 · Richard J. Rebello, Atara Posner, et al. · Nature Communications · 20
PDF
Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary
2023 · Atara Posner, Tharani Sivakumaran, et al. · Journal for ImmunoTherapy of Cancer · 19
PDF
Six-year experience of Australia’s first dedicated cancer of unknown primary clinic
2023 · Arielle van Mourik, Gina Tonkin-Hill, et al. · British Journal of Cancer · 16
PDF
Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis
2024 · Jeroen R. J. Willemse, Doenja M. J. Lambregts, et al. · European Journal of Nuclear Medicine and Molecular Imaging · 13
PDF
Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study
2020 · T. Sivakumaran, L. Mileshkin, et al. · Gynecologic Oncology · 11
Evaluating the Utility of 18 F-FDG PET/CT in Cancer of Unknown Primary
2024 · Tharani Sivakumaran, Anthony Cardin, et al. · Journal of Nuclear Medicine · 10
PDF
Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
2024 · Tanya L. Ross, Renhua Na, et al. · Gynecologic Oncology · 5
PDF
The evolution of molecular management of carcinoma of unknown primary
2024 · Tharani Sivakumaran, Richard W. Tothill, et al. · Current Opinion in Oncology · 5
Clinical impact of tissue of origin testing and mutation profiling in the Solving Unknown Primary Cancer (SUPER) national prospective study: Experience of the first two years.
2019 · Linda R. Mileshkin, Tharani Sivakumaran, et al. · Journal of Clinical Oncology · 4
Treatment patterns after poly-ADP ribose polymerase (PARP) inhibitors in epithelial ovarian cancer patients
2022 · Tharani Sivakumaran, Michael Krasovitsky, et al. · International Journal of Gynecological Cancer · 2
Solving unknown primary cancer with earlier diagnosis - the SUPER-ED trial: study protocol for a stepped-wedge cluster randomised controlled trial to support earlier diagnosis for people presenting with malignancy of undefined primary origin
2025 · Anna Ugalde, Richard W. Tothill, et al. · BMC Cancer · 1
PDF
Evaluating the utility of fluorine-18 fluorodeoxyglucose (18F-FDG)-positron emission tomography (PET)/ computed tomography (CT) scan in cancer of unknown primary.
2022 · Tharani Sivakumaran, Anthony Cardin, et al. · Journal of Clinical Oncology · 1
Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer
2019 · Vanessa L. Beesley, Tanya L. Ross, et al. · Asia-Pacific Journal of Clinical Oncology · 1
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
2026 · Tharani Sivakumaran, Timothy J. Akhurst, et al. · Journal of Clinical Oncology
PDF
762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
2025 · R.J. Rebello, T. Sivakumaran, et al. · Annals of Oncology
Understanding the clinical and molecular phenotype of cancer of unknown primary (CUP) with a lung cancer profile.
2025 · Sarah Williams, Tharani Sivakumaran, et al. · Journal of Clinical Oncology
76P Improving access to whole genome sequencing for patients with cancer of unknown primary using formalin-fixed paraffin embedded tissues and cell-free DNA
2024 · R.W. Tothill, R. Rebello, et al. · Annals of Oncology
Clinical impact of molecular profiling in the national prospective cohort Solving Unknown Primary Cancer (SUPER) study.
2024 · Tharani Sivakumaran, Matthew White, et al. · Journal of Clinical Oncology
Experience of a dedicated carcinoma of unknown primary clinic in an Australian comprehensive cancer centre
2021 · Arielle van Mourik, Gina Tonkin-Hill, et al. · Asia-Pacific Journal of Clinical Oncology
402 Treatment patterns post PARP inhibitor in epithelial ovarian cancer patients: results from an Australian, retrospective, multi-institute cohort study
2020 · T. Sivakumaran, M. Krasovitsky, et al. · International Journal of Gynecological Cancer
PDF
What is the impact of dose modification in adjuvant chemotherapy for ovarian cancer?
2018 · Tharani Sivakumaran, Linda Mileshkin · Gynecology and Pelvic Medicine
Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.
2018 · Tharani Sivakumaran, Linda R. Mileshkin, et al. · Journal of Clinical Oncology
Works count: 25
Citation count: 136
H-index: 7
I10-index: 7
Year
Topic
Type